ArticleMedicine2025
HPV infection trends in Inner Mongolia across the pre- and pandemic periods of COVID-19: A single-center analysis.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study compares overall and risk-category (high-risk vs low-risk) human papillomavirus (HPV) infection rates among women undergoing health examinations in Hohhot, Inner Mongolia, before and during the COVID-19 pandemic. We analyzed 3714 women tested for HPV from January 2020 to December 2024. The participants were divided into 2 groups based on the local epidemiological timeline in Inner Mongolia: a pre-pandemic group (January 2020-December 2022, when COVID-19 cases were sporadic under strict containment measures), and a pandemic group (January 2023-December 2024, after restrictions were lifted and community transmission became widespread). The primary outcomes were overall HPV positivity and high-risk versus low-risk HPV positivity. Group differences were assessed using chi-square tests (α = 0.05). The overall HPV infection rate was 17.56% (652/3714). The positivity rate was 18.02% in the pre-pandemic period versus 16.89% in the pandemic period. Across years, the overall positivity and the high-risk positivity peaked in 2021, with significant heterogeneity across years (overall χ²=28.512, P <.001; high-risk χ²=25.940, P <.001). High-risk HPV positivity exceeded low-risk positivity in all years. In this single-center cohort, the overall HPV positivity showed a slight decline during the pandemic period compared with the pre-pandemic period, while high-risk types remained more common than low-risk types. These findings underscore the need to maintain HPV screening and vaccination efforts during public health emergencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.